<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186068</url>
  </required_header>
  <id_info>
    <org_study_id>V-101-ROSE-202</org_study_id>
    <nct_id>NCT01186068</nct_id>
  </id_info>
  <brief_title>Dose Response Study of Patients With Erythematous Rosacea</brief_title>
  <official_title>A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of the Dose-Response Profile of V-101 Cream in Subjects With Erythematous Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vicept Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accenture</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vicept Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the dose-response relationship (effect) of four
      concentrations of V-101 Cream in patients with erythematous(redness) rosacea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients must have moderate to severe erythematous (facial redness) rosacea

        -  Male and female patients must be at least 18 years old and in good general health

        -  Female patients must not be pregnant or nursing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician's Erythema Assessment</measure>
    <time_frame>Day 28 visit</time_frame>
    <description>Physician visual evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject's Self Assessment</measure>
    <time_frame>28 Day Visit</time_frame>
    <description>Patient assesses their condition</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Erythematous (Type One) Rosacea</condition>
  <arm_group>
    <arm_group_label>V-101 Cream 0.01% Concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V-101 Cream 0.06% Concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V-101 Cream 0.1% Concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V-101 Cream 0.15% Concentration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cream without an active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V-101</intervention_name>
    <description>Cream QD</description>
    <arm_group_label>V-101 Cream 0.01% Concentration</arm_group_label>
    <arm_group_label>V-101 Cream 0.06% Concentration</arm_group_label>
    <arm_group_label>V-101 Cream 0.1% Concentration</arm_group_label>
    <arm_group_label>V-101 Cream 0.15% Concentration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>vehicle</intervention_name>
    <description>Cream QD</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or females at least 18 years of age

          -  diagnosis of stable erythematous rosacea

          -  &lt; 3 inflammatory lesions

          -  in good general health

          -  females must be non-pregnant and non-lactating

          -  must be willing to sign a consent form

        Exclusion Criteria:

          -  have ocular, phymatous or other types of rosacea

          -  allergy to any ingredient in study drug

          -  participation in other investigational studies within 30 days of enrollment

          -  use of systemic steroids within 28 days of Baseline

          -  use of tetracycline antibiotics within 28 days of baseline

          -  use of products containing oxymetazoline within 14 days of baseline

          -  use of topical steroids witin treatment area 14 days prior to baseline

          -  use of Rx or OTC products for treatment of acne or rosacea within 14 days of baseline

          -  use of any product for reducing redness within the treatment area witin 14 days prior
             to baseline

          -  use of monoamine oxidase (MAO) inhibitors

          -  use of niacin &gt;/= 500mg/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacy R Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Therapeutics Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael T Jarratt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermResearch, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leslie S Baumann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baumann Cosmetic &amp; Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph F Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert T Matheson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Medical Research Center, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel M Stewart, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>DBA Michigan Center for Skin Care Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Tschen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Dermatology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baumann Cosmetic &amp; Research Institute</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DBA Michigan Center for Skin Care Research</name>
      <address>
        <city>Clinton Twp</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2010</study_first_submitted>
  <study_first_submitted_qc>August 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2010</study_first_posted>
  <last_update_submitted>November 22, 2010</last_update_submitted>
  <last_update_submitted_qc>November 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Operating Officer</name_title>
    <organization>Vicept Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>Rosacea, erythema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

